Advances in Tau Therapeutics
Description
In this presentation we will discuss the rationale for targeting tau in neurodegenerative diseases, and recent advances in clinical trials targeting tau.
Behavioral Neurology and Dementia: Therapeutic Advances in Neurodegenerative Diseases*
Date: September 16, 2025
Time: 11:00 am to 12:30 pm
Track: Traditional Special Interest Group (SIG)
Session Description
This session will review therapeutic advances in the treatment of patients with early-symptomatic Alzheimer disease and related dementias, discussing real-world experience with emergent therapeutics for early-symptomatic Alzheimer disease (i.e., anti-amyloid therapies), promising developments relevant to the treatment of Lewy body disease (i.e., insights and results from the SHIMMER Trial of CT1812), and therapeutics in development for patients with tauopathies.
Learning Objectives
At the conclusion of the session, attendees should be able to:
- Apply real-world experience to inform patient selection and monitoring of response to FDA-approved anti-amyloid therapies.
- Recognize outstanding questions that need to be addressed to inform long-term use of anti-amyloid therapies in patients with early-symptomatic Alzheimer disease.
- Discuss emergent therapies for patients with Alzheimer disease, Lewy body disease, and frontotemporal lobar degeneration.
Speakers
- (Speaker) Lawren Vandevrede, MD, PhD
- (Speaker) John Dickson, MD, PhD
- (Speaker) James E. Galvin, MD, MPH
Real-World Clinical Experience with Anti-Amyloid Therapy
Description
This presentation focuses on the real-world clinical experience with anti-amyloid therapy in an academic health system.
Speakers
Advances in the Treatment of Lewy Body Disease
Description
In this presentation we will review the current state-of-the-science of Lewy body dementia and recent clinical trials with potential disease modifying medications.